Sarcosine is a competitive inhibitor of glycine type 1 transporter. We hypothesized that it may have analgesic and anti-neuropathic efficacy by a dual action: affecting neurotransmission in the prefrontal cortex as well as within the spinal cord. In rats with spared nerve injury (SNI) oral sarcosine reduced mechanical sensitivity for the injured limb (anti-neuropathy or anti-allodynia) as well as for the uninjured limb (analgesia), showing better dose efficacy for the injured limb. Intrathecal administration of sarcosine was more effective in reducing mechanical sensitivity for the uninjured paw. In contrast, prefrontal cortex infusions of sarcosine acutely reduced mechanical sensitivity for the injured paw. Repeated daily oral sarcosine induced anti-neuropathy, observed only after days of repeated treatment; this long-term effect disappeared a few days after treatment cessation. The findings indicate that manipulating glycine-T1 transporter at multiple central sites can induce acute analgesia, as well as acute and long-term reduction in neuropathic pain behavior. Analgesic effects seem primarily mediated through spinal cord circuitry while anti-neuropathic effects seem mediated through prefrontal cortex circuitry, most likely through distinct molecular pathways. The results suggest that such an approach may provide a novel venue for treating clinical pain conditions. Ó
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Introduction
Chronic neuropathic pain conditions have a huge impact on society and on health care. Mechanisms underlying such conditions, especially in human clinical states, remain poorly understood, as a result available therapeutic approaches are limited and lack efficacy. Studies in animal models have demonstrated a long list of changes in the periphery as well as in the spinal cord that ensue following a neuropathic injury and are potential therapeutic targets [30, 34] . Additionally, accumulating evidence from human brain imaging studies point towards cortical reorganization in chronic pain, many of which tightly correlate to clinical characteristics [1] [2] [3] 14, 19, 29, 32] , implying that targeting components of this circuitry may also have therapeutic benefits. The present study attempts to take advantage of this new knowledge and tests the efficacy of manipulating neuropathic pain behavior by modulating glycinergic pathways in the cortex as well as the spinal cord.
We recently demonstrated that manipulating glycine availability at the NMDA receptor in the cortex, specifically in the medial prefrontal cortex (mPFC) and the amygdala, can give rise to longterm reduction in neuropathic pain behavior [26] . The study used oral or central infusions of D-cycloserine (DCS), a partial agonist at the strychnine-insensitive glycine-recognition site on the NMDA receptor complex [13] , and showed that oral and mPFC, but not intrathecal, DCS reduce tactile sensitivity in rat models of neuropathic pain. DCS appears to modulate tactile sensitivity only for the neuropathic injured limb, in a dose-dependent manner and with increasing efficacy for up to 3 weeks of oral treatment. The study demonstrates a potential therapeutic drug for chronic pain with a purely supraspinal target. Here we study manipulating the glycine transporter as an alternate route with which availability of glycine in the central nervous system can be altered, and test its effects on pain behavior acutely and during long-term treatment.
Glycine is a major inhibitory neurotransmitter in the spinal cord and the brainstem, and participates in excitatory neurotransmission by modulating NMDA receptors throughout the central 
